ETP-ALL Cell Strain ZYXY-T1 for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T-cell acute lymphoblastic leukemia (T-ALL), particularly the subtype early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), are limited, with no established cell strain for research, leading to restricted basic and clinical research, poor prognosis, and high recurrence rates.
Innovation Solution
Development of the immortalized human T-lymphoblastic leukemia/lymphoma cell strain ZYXY-T1, which exhibits typical ETP-ALL surface antigen characteristics, specifically high expression of CD34, and can be used for studying pathogenesis, drug screening, and developing therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional combined chemotherapy is used for ETP-ALL treatment, then remission rate can reach 90%-95%, but relapse occurs for nearly one-third of patients and overall five-year survival rate is only about 50%
Solution Approach 1:
The patent creates an immortalized cell strain ZYXY-T1 that copies the biological characteristics of ETP-ALL patients, including surface antigen expression patterns (CD34 high, CD1a negative, CD8 negative). This cell strain serves as a reproducible model to study disease mechanisms and test therapeutic interventions, addressing the limitation of using patient samples that cannot be continuously cultured.
Solution Approach 2:
The cell strain ZYXY-T1 acts as an intermediary between ETP-ALL patients and research/clinical applications. It mediates the translation of patient-specific disease characteristics into a standardized platform for mechanistic studies, drug screening, and therapeutic development, thereby improving the duration of action for treatment effects.
2Adaptability or versatility
If no ETP-ALL cell strain is established, then basic research and clinical research can be conducted, but research is greatly restricted and no effective treatment strategies can be developed
Solution Approach 1:
The patent establishes cell strain ZYXY-T1 that replicates the key biological features of ETP-ALL, including suspension growth pattern, high CD34 expression, and negative expression of CD1a and CD8. This copying enables unlimited research applications from basic mechanism studies to clinical trial preparation, while maintaining reliable representation of the disease state.
Solution Approach 2:
The cell strain serves multiple functions simultaneously: it can be used for studying pathogenesis mechanisms, screening novel therapeutic drugs, evaluating combination therapies, and preparing animal models. This multi-functionality greatly expands research capability while providing a reliable platform for developing effective treatment strategies.
3Measurement precision
If patient specimens are used for research, then authentic disease characteristics can be studied, but samples cannot be continuously subcultured and experiments cannot be repeatedly conducted
Solution Approach 1:
The patent creates a cellular copy ZYXY-T1 that preserves the authentic disease characteristics of ETP-ALL patients, including surface antigen expression profile (CD34+, CD1a-, CD8-). Unlike primary patient samples, this cell strain can be continuously subcultured and passed through multiple generations while maintaining consistent biological properties, enabling repeated experiments.
Solution Approach 2:
The cell strain enables continuous subculturing and long-term experimentation without the limitation of finite patient samples. The immortalized nature of ZYXY-T1 allows uninterrupted research activities, maintaining both measurement precision of disease characteristics and productivity through repeated experimental cycles.
Data Source
AI summary
The present application discloses a human T-lymphoblastic leukemia/lymphoma cell strain named as ZYXY-T1, and its construction method and use thereof. It was conserved in China Center for Type Culture Collection (Wuhan, China) on Jan. 20, 2021, and the preservation number was CCTCC NO: C202143. The present application is obtained by separating mononuclear cells from peripheral blood of one ETP-ALL patient, and culturing the cells in vitro for continuous natural passage. The strain has the typical surface antigen expression characteristics of ETP-ALL, that is, it does not express CD1α, CD5 or CD8, and highly expresses a stem cell marker CD34, and has good proliferation ability in vitro and tumorigenesis ability in vivo; it can be used as a cell material to study the occurrence and development mechanism of ETP-ALL, and can also be used to screen and evaluate ETP-ALL drugs to guide clinical medication.